Data from retrospective look at our patients with diabetes, taking metformin and having a procedure with contrast.
and oftentimes absence of timely follow-up after contrast administration. Exclusion criteria were: immediate hospitalization after the CT scan and CT scan during hospitalization given that metformin is stopped upon admission and renal function can be impacted by several other factors in the hospital.
Data Collection
Picture Archiving and Communication System (PACS) records were reviewed in a reverse chronological manner to identify consecutive patients who had received intravenous contrast for CT scans.
Statistical Analysis
Baseline characteristics of all study participants were summarized using descriptive statistics. Categorical variables were described using counts and percentages and continuous variables were described using means ± standard deviations (SD).
To determine if there was a change in Cr (and eGFR) after contrast, overall t-tests were performed including all study subjects (n=130) and study subjects with pre-contrast eGFR < 60 ml/min/1.73m 2 . Since the laboratory uses the non-African American MDRD equation to report eGFR, the eGFR was adjusted by a factor of 1.2 for participants with African American ethnicity. In addition, all records were reviewed to determine the number of patients that developed AKI after contrast administration.
Results: Post-contrast eGFR (ml/min/1.73m 2 ) 75 ± 26 *Data from time of first computed tomography scan used to describe baseline characteristics # Normal range for creatinine is 0.6-1.3 mg/dL. Abbreviations: ACEI -angiotensin converting enzyme inhibitor, ARB -angiotensin receptor blocker, NSAIDs -non-steroidal anti-inflammatory drugs, eGFR -estimated glomerular filtration rate Includes all CT scans of study subjects with pre-contrast eGFR < 60 ml/min/1.73m 2 c Includes baseline (first CT scan) of all study subjects (n=130) d Includes baseline (first CT scan) of study subjects with pre-contrast eGFR < 60 ml/min/1.73m 2 a Includes all CT scans from all 130 study subjects b Includes all CT scans of study subjects with pre-contrast eGFR < 60 ml/min/1.73m 2 c Includes baseline (first CT scan) of all study subjects (n=130) d Includes baseline (first CT scan) of study subjects with pre-contrast eGFR < 60 ml/min/1.73m 2 Models adjust for: age, sex, BMI, diabetes duration and last HbA1c. a All study subjects included in the analysis. b Study subjects with pre-contrast eGFR < 60 ml/min/1.73m 2 included in the analysis. Review of individual patient records showed that of the 130 study participants, a total of 4 (3%) developed AKI (pre-contrast Cr: 1.38, 1.48, 1.35, and 1.24 mg/dL and post-contrast Cr:
1.85, 1.83, 1.83 and 1.89 mg/dL respectively, obtained 4-16 days post-contrast). They all had a pre-contrast eGFR of < 60 ml/min/1.73m 2 , had hypertension, were taking an ACEI or ARB and received some intravenous hydration pre-contrast. Three of the patients were on a diuretic and had albuminuria, and one patient had a prior episode of renal failure. Three of the patients were eventually restarted and continued on metformin. None of these patients had a lactate level drawn or was hospitalized. Renal function returned to baseline after anywhere from 2 weeks to 5 months.
